LithoVue Elite system's real-time IRP monitoring may enhance flexible ureteroscopy for larger stones, offering data-driven pressure management. CVAC 2.0 ureteroscope demonstrates safety and efficacy ...
Non-muscle invasive bladder cancer treatments have expanded beyond BCG, offering alternatives to radical cystectomy with flexible dosing and scheduling. Muscle-invasive bladder cancer management is ...
An expert discusses how the KEYNOTE-905 trial findings established pembrolizumab as a groundbreaking perioperative immunotherapy approach for cisplatin-ineligible muscle-invasive bladder cancer, ...
Hear from 5 experts as they recap some of the top data from this year's ESMO Congress. Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates ...
Panelists discuss how IsoPSA’s long-term predictive performance supports safer follow-up strategies and greater confidence in risk-based management. Panelists discuss how IsoPSA’s predictive ...
Chandler Park, MD, MSc, FACP, interviews urologist Neal D. Shore, MD, FACS, on the top updates in prostate cancer and bladder cancer at the 2025 European Society for Medical Oncology Congress. At the ...
Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate cancer. The trial showed consistent benefits across clinical endpoints, ...
Discover innovative approaches to treating premature ejaculation with insights from leading experts in sexual health and urology. At the 2025 Sexual Medicine Society of North America meeting in ...
The Altaviva device offers a minimally invasive treatment for urge urinary incontinence, with patients returning home with therapy activated. It features a 15-year battery lifespan, MRI compatibility, ...
Neuspera's iSNM system provides a battery-free alternative to traditional SNM, reducing complications and surgeries for UUI patients. The SANS-UUI trial showed 84.2% of patients achieved at least a 50 ...
Panelists discuss how real-world data from a recent Mayo Clinic study confirms the promising efficacy and favorable safety profile of nadofaragene firadenovec in BCG-unresponsive non–muscle-invasive ...
UGN-102's NDA is supported by the phase 3 ENVISION trial, showing a 79.6% complete response rate at 3 months for LG-IR-NMIBC patients. The FDA is evaluating if the observed duration of response is due ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback